Supercharged immune cells aim to stop lymphoma comeback

NCT ID NCT02663297

Ongoing Disease control Sponsor: UNC Lineberger Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new treatment for people with Hodgkin or non-Hodgkin lymphoma who have had a stem cell transplant. The treatment uses the patient's own T cells, which are modified in a lab to recognize and attack cancer cells that carry a protein called CD30. The main goal is to find a safe dose and see if these engineered cells can prevent the cancer from coming back.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ATLCAR.CD30 cells (engineered T cells that target CD30 on lymphoma cells)
What this could lead to: If successful, this approach could help prevent lymphoma from returning after a stem cell transplant, offering a new way to keep the cancer in check.
What could go wrong: This is an early phase 1 trial with only 18 participants, so it is primarily testing safety and dosing. The treatment may not work as hoped, and side effects like cytokine release syndrome are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CD30+ LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anaplastic large cell lymphoma classic Hodgkin lymphoma diffuse large B-cell lymphoma Hodgkins lymphoma immune system disorder immunoproliferative disorder lymphatic system disorder lymphoma lymphoma, non-Hodgkin, familial lymphoproliferative syndrome mycosis fungoides neoplasm Neoplasms by Histologic Type non-Hodgkin lymphoma primary cutaneous T-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HODGKIN DISEASE IMMUNE SYSTEM DISEASES IMMUNOPROLIFERATIVE DISORDERS LYMPHATIC DISEASES LYMPHOMA LYMPHOMA, NON-HODGKIN LYMPHOPROLIFERATIVE DISORDERS NEOPLASMS NEOPLASMS BY HISTOLOGIC TYPE

Contacts and locations

Locations

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill

Chapel Hill, North Carolina, 27599, United States
Wake Forest University

Winston-Salem, North Carolina, 27157, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.